Abstract
Chondroitin sulfate (CS), a polysaccharide moiety of proteoglycans, is one of the major components of the extracellular matrix in the central nervous system and is involved in various cellular events in the formation and maintenance of the neural network. In the developing brain, CS in the milieu of neural stem/progenitor cells (NSPCs) is believed to participate in the regulation of their functions such as proliferation and differentiation. NSPCs are expected to act as a potent cell type in cell replacement therapy for neurodegeneration in various neurological diseases. Recently, it has been shown that transplantation of NSPCs combined with removal of extracellular CS from the host nervous tissues gives a satisfactory outcome in some animal models of nervous tissue injuries including neonatal hypoxic-ischemic injury and adult spinal cord injury. The combination of cell transplantation with modification of the extracellular matrix of the host tissue could be a novel strategy for the treatment of incurable neurodegenerative diseases.
Keywords: Chondroitin sulfate, proteoglycan, niche, stem cells, transplantation, extracellular matrix, neurodegenerative diseases
Current Stem Cell Research & Therapy
Title: Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification
Volume: 4 Issue: 3
Author(s): Yoshiaki Sato and Atsuhiko Oohira
Affiliation:
Keywords: Chondroitin sulfate, proteoglycan, niche, stem cells, transplantation, extracellular matrix, neurodegenerative diseases
Abstract: Chondroitin sulfate (CS), a polysaccharide moiety of proteoglycans, is one of the major components of the extracellular matrix in the central nervous system and is involved in various cellular events in the formation and maintenance of the neural network. In the developing brain, CS in the milieu of neural stem/progenitor cells (NSPCs) is believed to participate in the regulation of their functions such as proliferation and differentiation. NSPCs are expected to act as a potent cell type in cell replacement therapy for neurodegeneration in various neurological diseases. Recently, it has been shown that transplantation of NSPCs combined with removal of extracellular CS from the host nervous tissues gives a satisfactory outcome in some animal models of nervous tissue injuries including neonatal hypoxic-ischemic injury and adult spinal cord injury. The combination of cell transplantation with modification of the extracellular matrix of the host tissue could be a novel strategy for the treatment of incurable neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Sato Yoshiaki and Oohira Atsuhiko, Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification, Current Stem Cell Research & Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488809789057419
DOI https://dx.doi.org/10.2174/157488809789057419 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
Current Drug Targets - CNS & Neurological Disorders The Epigenetic Mechanisms Involved in Chronic Pain in Rodents: A Mini- Review
Current Neuropharmacology Research on the Possibility of Overcoming Traumatic Paraplegia and Its First Clinical Results
Current Pharmaceutical Design EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Beyond Rodent Models of Pain: Non-Human Primate Models for Evaluating Novel Analgesic Therapeutics and Elaborating Pain Mechanisms
CNS & Neurological Disorders - Drug Targets Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer’s Disease
Current Nanoscience Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
CNS & Neurological Disorders - Drug Targets Modulators of Pain: Bv8 and Prokineticins
Current Neuropharmacology Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Group I Metabotropic Glutamate Receptors: Involvement in Drug-Seeking and Drug-Induced Plasticity
Current Molecular Pharmacology Controlling Apoptosis by Inhibition of Caspases
Current Medicinal Chemistry Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1)
Current Topics in Medicinal Chemistry